Floatz logo

Sgr-1505

Primary Effusion Lymphoma

Schrödinger, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Primary Effusion Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BBB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB

View all 39 →

Same molecule, other indications

Sgr-1505 is also rated in:

MALT lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderlyDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →